Chivu-Economescu Mihaela, Necula Laura, Matei Lilia, Dragu Denisa, Bleotu Coralia, Diaconu Carmen C
Department of Cellular and Molecular Pathology, Stefan S. Nicolau Institute of Virology, Bucharest, Romania.
Faculty of Medicine, Titu Maiorescu University, Bucharest, Romania.
Front Med (Lausanne). 2021 Sep 28;8:749250. doi: 10.3389/fmed.2021.749250. eCollection 2021.
Liquid biopsy represents an exciting new area in the field of cancer diagnosis and management, offering a less invasive and more convenient approach to obtain a time-point image of the tumor burden and its genomic profile. Samples collected from several body fluids, mostly blood, can be used to gain access to circulating tumor cells and DNA, non-coding RNAs, microRNAs, and exosomes, at any moment, offering a dynamic picture of the tumor. For patients with GC, the use of blood-based biopsies may be particularly beneficial since tissue biopsies are difficult to obtain and cause real distress to the patient. With advantages such as repeatability and minimal invasion, it is no wonder that the field of liquid biopsy has received tremendous attention. However, the abundance of studies, involving a wide range of assays with different principles, prevented for the moment the reproducibility of the results and therefore the translation into the clinic of liquid biopsy. In this review, we present the latest technical development and data on circulating biomarkers available through liquid biopsy in gastric cancer with an emphasis on their clinical utility in areas such as cancer screening, prognostic stratification, and therapeutic management.
液体活检是癌症诊断和治疗领域一个令人兴奋的新领域,它提供了一种侵入性较小且更便捷的方法,以获取肿瘤负荷及其基因组概况的时间点图像。从多种体液(主要是血液)中采集的样本可用于随时获取循环肿瘤细胞和DNA、非编码RNA、微小RNA和外泌体,从而提供肿瘤的动态图像。对于胃癌患者,基于血液的活检可能特别有益,因为组织活检难以获取且会给患者带来实际痛苦。由于具有可重复性和微创等优点,液体活检领域受到了极大关注也就不足为奇了。然而,大量涉及各种不同原理检测方法的研究目前阻碍了结果的可重复性,进而阻碍了液体活检在临床中的应用。在这篇综述中,我们介绍了通过液体活检可获得的胃癌循环生物标志物的最新技术进展和数据,重点阐述了它们在癌症筛查、预后分层和治疗管理等领域的临床应用价值。